

Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S
Form 6-K
February 11, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

February 11, 2008

NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)

NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____

NOVO NORDISK FILES ANNUAL REPORT WITH THE SEC

NOVO NORDISK A/S HAS FILED ITS ANNUAL REPORT 2007 ON FORM 20-F FOR THE FINANCIAL
YEAR 2007 WITH THE US SECURITIES AND EXCHANGE COMMISSION (SEC), INCORPORATING BY
REFERENCE THE NOVO NORDISK A/S ANNUAL REPORT 2007. THE REPORTS ARE AVAILABLE AT
THE SEC'S WEBSITE, WWW.SEC.GOV AS WELL AS AT: NOVONORDISK.COM - INVESTORS -
DOWNLOAD CENTRE (LISTED UNDER 2007).

Edgar Filing: NOVO NORDISK A S - Form 6-K

Shareholders and ADR holders may receive a hard copy of the annual reports free of charge upon request by filling out a request form at novonordisk.com/investors/download-centre or upon request to either tel no +1 (609) 712-8127 or by e-mail to cqfr@novonordisk.com. When e-mailing, please state the exact mailing address and the document(s) you wish to receive.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:

Media:

Outside North America:
Mike Rulis
Tel: (+45) 4442 3573
mike@novonordisk.com

Investors:

Outside North America:
Mads Veggerby Lausten
Tel: (+45) 4442 7945
mlau@novonordisk.com

Hans Rommer
Tel: (+45) 4442 4765
hrrmm@novonordisk.com

In North America:
Sean Clements
Tel: (+1) 609 514 8316
secl@novonordisk.com

In North America:
Christian Qvist Frandsen
Tel: (+1) 609 919 7937
cqfr@novonordisk.com

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: February 11, 2008

NOVO NORDISK A/S

Lars Rebien Sorensen,
President and Chief Executive Officer